

REFERENCES

- Akase T, Shimada T, Terabayashi S, Ikeya Y, Sanada H, Aburada M. Antiobesity effects of *Kaempferia parviflora* in spontaneously obese type II diabetic mice. **J Nat Med** 2011; 65: 73-80.
- Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. **Adv Drug Deliver Rev** 2001; 46: 27-43.
- Ashford M. Bioavailability-physicochemical and dosage form factors. In: Aulton ME, editor. **Aulton's Pharmaceutics: The design and manufacture of medicines**. 3rd ed. Hungary: Elsevier; 2007. p. 286-323.
- Azuma T, Tanaka Y, Kikuzaki H. Phenolic glycosides from *Kaempferia parviflora*. **Phytochem** 2008; 69(15): 2743-2748.
- Azuma T, Kayano SI, Matsumura Y, Konishi Y, Tanaka Y, Kikuzaki H. Antimutagenic and α -glucosidase inhibitory effects of constituents from *Kaempferia parviflora*. **Food Chem** 2011; 125: 471-475.
- Bachhav YG, Patravale VB. SMEDDS of glyburide: formulation, *in vitro* evaluation, and stability studies. **AAPS Pharm Sci Tech** 2009; 10(2): 482-487.
- Banjerdpongchai R, Suwannachot K, Rattanapanone V, Sripanidkulchai B. Ethanolic rhizome extract from *Kaempferia parviflora* Wall. Ex. Baker induced apoptosis in HL-60 cells. **Asian Pacific J Cancer Prev** 2008; 9: 595-600.
- Biddlecombe B, Callejas S, Evans G. Mass spectrometry and quantitative bioanalysis. In: Evans G, editor. **A handbook of bioanalysis and drug metabolism**. Florida: CRC Press; 2004. p. 69-76.
- Borchardt RT. Biological models to assess drug bioavailability. In: Testa B, Waterbeemd H, Folkers G, Guy R, editors. **Pharmacokinetic optimization in drug research: biological, physicochemical, and computational strategies**. Germany: Konrad Triltsch; 2001. p. 119.
- Bray BJ, Brennan NJ, Perry NB, Menkes DB, Rosengren RJ. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. **Life Sci** 2002; 70: 1325-1335.

- Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. **Adv Drug Deliver Rev** 2007; 59: 645-666.
- Buxton IL. **Goodman & Gilman's the pharmacological basis of therapeutics**. New York: McGraw-Hill; 2006.
- ...**Caco-2 permeability assay** [online] 2007 [cited 2010 Jul 20]. Available from: <http://www.apredica.com/caco2.php>.
- Cannon JB, Long MA. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery-part II: oral applications. In: Liu R, editor. **Water-insoluble drug formulation**. 2nd ed. Florida: CRC Press; 2008. p. 240.
- Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S. Hyperforin contributes to the hepatic CYP3A-inducing effect of *Hypericum perforatum* extract in the mouse. **Toxicol Sci** 2003; 75: 25-30.
- Castillo T, Koop DR, Kamimura S, Triadafilopoulos G, Tsukamoto H. Role of cytochrome P-450 2E1 in ethanol-, carbontetrachlorine- and iron-dependent microsomal lipid peroxidation. **Hepatology** 1992; 16(4): 992-996.
- Chaipech S, Morikawa T, Ninomiya K, Yoshikawa M, Pongpiriyadacha Y, Hayakawa T, et al. New flav-3-en-3-ol glycosides, kaempferiaosides C and D, and acetophenone glycosides, kaempferiaosides E and F, from the rhizomes of *Kaempferia parviflora*. **J Nat Med** 2011; doi: 10. 1007/s11418-011-0611-1.
- Chaturapanich G, Chaiyakul S, Verawatnapakul V, Pholpramool C. Effects of *Kaempferia parviflora* extracts on reproductive parameters and spermatoc blood flow in male rats. **Reproduction** 2008; 136: 515-522.
- Chen Y, Li G, Wu X, Chen Z, Hang J, Qin B, et al. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. **Biol Pharm Bull** 2008; 31(1): 118-125.
- Chivapat S, Chavalittumrog P, Phadungpat S, Pama KK, Chansuvanich N, Attawish A, et al. Acute and chronic toxicity study of *Kaempferia parviflora* Wall ex. Baker powder. **J Thai Trad & Alter Med** 2004; 2(2): 3-16.
- Chivapat S, Chavalittumrog P, Attawish A, Rungsipipat A. Chronic toxicity study of *Kaempferia parviflora* Wall ex. extract. **Thai J Vet Med** 2010; 40(4): 377-383.

- Coleman MD. **Human drug metabolism: an introduction**. 2nd ed. New Jersey: Wiley & Sons; 2010.
- Cornorrs KA. The stability of cyclodextrin complexes in solution. **Chem Rev** 1997; 97: 1325-1357.
- Correia MA. Drug biotransformation. In: Katzung BG, editor. **Basic and clinical pharmacology**. 9th ed. Singapore: McGraw-Hill; 2004. p. 51-63.
- Correia MA. Drug biotransformation. In: Katzung BG, editor. **Basic and clinical pharmacology**. 11th ed. Singapore: McGraw-Hill; 2009.
- Cui J, Yu B, Zhao Y, Zhu W, Lou H, Zhai G. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. **Int J Pharm** 2009; 371: 148-155.
- Cui S, Zhao C, Chen D, He Z. Self-microemulsifying drug delivery systems (SMEDDS) for improving in vitro dissolution and oral absorption of *Pueraria lobata* isoflavone. **Drug Dev Ind Pharm** 2005; 31: 349-356.
- Davis ME, Brewster ME. Cyclodextrin-based pharmaceuticals: past, present, and future. **Nat Rev Drug Discov** 2004; 3: 1023-1035.
- Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. **AAPS Pharm Sci Tech** 2010; 11(1): 314-321.
- Ducharme J, Dudley AJ, Thompson RA. Pharmacokinetic issues in drug discovery. In: Rang HP, editor. **Drug discovery and development: technology in transition**. China: Elsevier; 2006. p. 141-161.
- Dudda A, Kulzel GU. Metabolism studies in vitro and in vivo. In: Vogel HG, Hock FJ, Maas J, Mayer D, editors. **Drug discovery and evaluation: safety and pharmacokinetic assays**. Germany: 2006. p. 493-499.
- Eddershow P, Dickins M. Phase I metabolism. In: Evans G, editor. **A handbook of bioanalysis and drug metabolism**. Boca Raton: CRC press; 2004. p. 209.
- Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. **Chem Res Toxicol** 1991; 4(4): 391-407.
- Gonzalez FJ, Tukey RH. Drug metabolism. In: Goodman LS, Gilman A, editors. **The pharmacological basis of therapeutics**. London: Macmillan; 2008. p. 48-56.

- Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. **Biomed & Pharmacother** 2004; 58: 173-182.
- Habucky K. Methods to assess absorption in drug discovery. In: Welling PG, Tse FS, editors. **Pharmacokinetics: regulation, industrial, academic perspectives**. 2nd ed. New York: Marcel Dekker, Inc; 1995. p. 21-34.
- Hawiset T, Muchimapura S, Wattanathorn J, Sripanidkulchai B. Screening neuropharmacological activities of *Kaempferia parviflora* (Krachai Dam) in healthy adult male rats. **Am J Applied Sci** 2011; 8(7): 695-702.
- Hedaya MA. **Basic pharmacokinetics**. New York: CRC Press; 2007.
- Higuchi T, Connors KA. Phase-solubility techniques. **Adv Anal Chem Instrum** 1965; 4: 117-212.
- Jarukamjorn K, Don-in K, Mekjaruskun C, Laha T, Daodee S, Pearaksa P, et al. Impact of *Andrographis paniculata* crude extract on mouse hepatic cytochrome P450 enzymes. **J Ethnopharmacol** 2006; 105: 464-467.
- Jitjaingam A, Kakaew A, Saenphet K, Saenphet S, Aritajat S. Effects of *Kaempferia parviflora* Wall. Ex Bake on reproductive organs, hematology, and kidney function of male rats. In: **The 31st Congress on Science and Technology of Thailand** at Suranaree university of Technology; 2005 Oct 18-20; Nakornratchasima, Thailand: 2005.
- Ioannides C, Barnett CR, Irizer A, Flatt PR. Expression of cytochrome P450 proteins in disease. In: Ioannides C, editor. **Cytochrome P450: metabolic and toxicological aspects**. Boca Raton: CRC Press, 1996. p. 301-327.
- Kim SG, Williams D, Schuetz E, Guzelian P, Novak R. Pyridine induction of cytochrome P-450 in the rat: role of P-450j (alcohol inducible form) in pyridine N-oxidation. **J Pharmacol Exp Ther**. 1988; 246: 1175-1181.
- Kimoto T, Takanashi M, Mukai H, Ogawara KI, Kimura T, Higaki K. Effect of adrenergic stimulation on drug absorption via passive diffusion in Caco-2 cells. **Int J Pharm** 2009; 368: 31-36.
- Kittichanun C, Phivthong-ngam L, Niwattisaiwong N, Piyachaturawut P, Suksamran A, Apipalakul K, et al. Effects of *Curcuma comosa* extracts on hepatic cytochrome P450 activities in rats. **J Health Res** 2010; 24(1): 1-6.

- Kummee S, Tewtrakul S, Subhadhirasakul S. Antimicrobial activity of the ethanol extract and compounds from the rhizomes of *Kaempferia parviflora*.
Songklanakarin J Sci Technol 2008; 30(4): 463-466.
- Leardkamolkarn V, Tiemyuyen S, Sripanidkulchai B. Pharmacological activity of *Kaempferia parviflora* extract against human bile duct cancer cell lines.
Asian Pacific J Cancer Prev 2009; 10: 695-698.
- Lee K, NG C, Brouwer K, Thakker DR. Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. **J Pharmacol Exp Ther** 2002; 303: 574-580.
- Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. **Clin Pharmacokinet** 1998; 35(5): 361-390.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. **J Biol Chem** 1951; 193: 265-275.
- Malakul W, Ingkaninan K, Sawasdee P, Woodman OL. The ethanolic extract of *Kaempferia parviflora* reduces ischemic injury in rat isolated hearts.
J Ethnopharmacol 2011a; 137(1): 184-191.
- Malakul W, Thirawarapan S, Ingkaninan K, Sawasdee P. Effects of *Kaempferia parviflora* Wall. Ex Baker in endothelial dysfunction in streptozotocin-induced diabetic rats. **J Ethnopharmacol** 2011b; 133: 371-377.
- Manchee G, Dickins M, Pickup E. Phase II enzymes. In: Evans G, editor.
A handbook of bioanalysis and drug metabolism. Boca Raton: CRC press; 2004. p. 222-223.
- McKendall M, Smith T, Anh K, Ellis J, McGee T, Foroozesh M, et al.
Methoxyflavone inhibitors of cytochrome P450. **J Chem Crystallogr** 2008; 38: 231-237.
- Meng J, Zheng L. Application of mixture experimental design to simvastatin apparent solubility predictions in the microemulsion formed by self-microemulsifying. **Drug Dev Ind Pharm** 2007; 33: 927-931.
- Montellano OD. The cytochrome P450 oxidative system. In: Woolf TF, editor.
Handbook of drug metabolism. New York: Marcel Dekker; 1999. p. 110-116.

- Na-Bangchang K, Wernsdorfer WH. **Fundamental Clinical Pharmacokinetics**. Bangkok: Faculty of Allied Health Sciences Thammasat University; 2001.
- Nakao K, Murata K, Deguchi T, Itoh K, Fujita T, Higashino M, et al. Xanthine oxidase inhibitory activities and crystal structures of methoxyflavones from *Kaempferia parviflora* rhizome. **Biol Pharm Bull** 2011; 34(7): 1143-1146.
- Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. **J Biol Chem** 1964; 239 (7): 2370-2378.
- Parlhad T, Rajenfrakumar K. Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. **J Pharmaceut Biomed Anal** 2004; 34: 333-339.
- Patanasetthanont D, Nagai J, Yumoto R, Murakami T, Sutthanut K, Sripanidkulchai B. Effects of *Kaempferia parviflora* extracts and their flavone constituents in P-glycoprotein function. **J Pharm Sci** 2007a; 96(1): 223-233.
- Patanasetthanont D, Nagai J, Matsuura C, Fukui K, Sutthanut K, Sripanidkulchai B, et al. Modulation of function of multidrug resistance associated-proteins by *Kaempferia parviflora* extracts and their components. **Eur J Pharmacol** 2007b; 566: 67-74.
- Patel D, Sawant KK. Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). **Drug Dev Ind Pharm** 2007; 33: 1318-1326.
- Patel MJ, Patel SS, Patel NM, Patel MM. A self-microemulsifying drug delivery system (SMEDDS). **Int J Pharm Sci and Res** 2010; 4(3): 29-35.
- Phurimsak C, Leardkamolkarn V. Screening for antiviral effect of Thai herbs; *Kaempferia parviflora*, *Ellipeopsis cherrevensis*, and *Stemona tuberosa* against dengue virus type 2. In: **The 31st Congress on Science and Technology of Thailand** at Suranaree university of Technology; 2005 Oct 18-20; Nakornratchasima, Thailand: 2005.
- Prasain JK, Wang CC, Barnes S. Mass spectrometric methods for the determination of flavonoids in biological samples. **Free Radic Biol Med** 2004; 37(9): 1324-1350.

- Putiyanan S, Chansakaow C, Phrutivorapongkul A, Charoensup W. Standard pharmacognostic characteristic of some Thai herbal medicine. **CMU J Nat Sci** 2008; 7(2): 239-255.
- Ramanathan DM, Lelacheur RM. Evolving role of mass spectrometry in drug discovery and development. In: Ramanathan R, editor. **Mass spectrometry in drug metabolism and pharmacokinetics**. USA: Wiley; 2009. p. 15-27.
- Rang HP, Dale MM, Ritter JM, Moore PK. **Pharmacology**. Toronto: Churchill Livingstone; 2003. p. 98-112.
- Rujjanawate C, Kanjanapothi D, Amornlerdpison D, Pojanagaroon S. Anti-gastric ulcer effect of *Kaempferia parviflora*. **J Ethnopharmacol** 2005; 102: 120-122.
- Sachan R, Khatri K, Kasture SB. Self-emulsifying drug delivery system a novel approach for enhancement of bioavailability. **Int J PharmTech Res** 2010; 2(3): 1738-1745.
- Sae-wong C, Tansakul P, Tewtrakul S. Anti-inflammatory mechanism of *Kaempferia parviflora* in murine macrophage cells (RAW 264.6) and in experimental animals. **J Ethnopharmacol** 2009; 124: 576-580.
- Sakuma T, Ohtake M, Katsurayama Y, Jarukamjorn K, Nemoto N. Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. **Drug Metab Dispos** 1999; 27: 379-384.
- Sawhney SK, Singh R. **Introductory practice biochemistry**. 2nd ed. UK: Harlow; 2005.
- Sawasdee P, Sabphon C, Sitthiwongwanit D, Kokpol U. Anticholinesterase activity of 7-methoxyflavones isolated from *Kaempferia parviflora*. **Phytother Res** 2009; 23: 1792-1794.
- Shargel L, Wu-Pong S, Yu A. **Applied biopharmaceutics and pharmacokinetics**. 5th ed. New York: McGraw-Hill; 2005.
- Sinko PJ. **Martin's physical pharmacy and pharmaceutical sciences: physical chemical and biopharmaceutical principles in pharmaceutical sciences**. 5th ed. USA: Lippincott Williams and Wilkins; 1993.

- Sripanidkulchai B, Tattawasart U, Junlatat J, Jindakul N, Sirisangtrakul W.
Antimutagenicity of extracts from dark and pale color rhizomes of *Kaempferia parviflora*. In: **The 10th World Congress on Clinical Nutrition**; 2004 Nov 3-5; Phuket, Thailand: 2004. p. 61.
- Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formation and delivery. **Pharm Res** 1997; 14(5): 556-567.
- Sudwan P, Saenphet K, Saenphet S, Suwansirikul S. Effect of *Kaempferia parviflora* Wall. Ex. Baker on sexual activity of male rats and its toxicity. **Southeast Asian J Trop Med Public Health** 2006; 37(3): 210-215.
- Sutthanut K, Sripanidkulchai B, Yenjai C, Jay M. Simultaneous identification and quantitation of 11 flavonoids constituents in *Kaempferia parviflora* by gas chromatography. **J Chromatography A** 2007; 1143: 227-233.
- Tietgen H. Chapter II.B Physicochemical properties. In: Vogel HG, Hock FJ, Maas J, Mayer D, editors. **Drug discovery and evaluation: safety and pharmacokinetic assays**. Germany: Springle; 2006. p. 399-408.
- Tep-areenan P, Sawasdee P, Randall M. Possible mechanisms of vasorelaxation for 5,7-dimethoxyflavone from *Kaempferia parviflora* in the rat aorta. **Phytother Res** 2010; 24: 1520-1525.
- Tewtrakul S, Subhadhirasakul S. Effects of compounds from *Kaempferia parviflora* on nitric oxide, prostaglandin E₂ and tumor necrosis factor-alpha productions in RAW264.7 macrophage cells. **J Ethnopharmacol** 2008; 120(1): 81-84.
- Tewtrakul S, Subhadhirasakul S, Kummee S. Anti-allergic activity of compounds from *Kaempferia parviflora*. **J Ethnopharmacol** 2008; 116: 191-193.
- Tiamyuyen S, Leardkamolkarn V. The effects of crude extracted *Kaempferia parviflora* on human cholangiocarcinoma cells proliferation, metastasis, and apoptosis. In: **The 31st Congress on Science and Technology of Thailand** at Suranaree university of Technology; 2005 Oct 18-20; Nakornratchasima, Thailand: 2005.
- Tong WQ, Wen H. Applications of complexation in the formulation of insoluble compounds. In: Liu R, editor. **Water-insoluble drug formulation**. 2nd ed. Florida: CRC Press; 2008. p. 134-154.

- Tsuji PA, Winn RN, Walle T. Accumulation and metabolism of the anticancer flavonoids 5,7-dimethoxyflavone compared to its unmethylated analog chrysin in the Atlantic killifish. **Chem Biol Interact** 2006; 164: 85-92.
- Ungell AL, Abrahamsson B. Biopharmaceutical support in candidate drug selection. In: Gibson M editor. **Pharmaceutical preformulation and formulations: a practical guide from candidate drug selection to commercial dosage form**. New York: Informa Healthcare; 2009. p. 144.
- Ungell AL, Artursson P. An overview of Caco-2 and alternatives for prediction of intestinal drug transport and absorption. In: Mannhold R, Kubinyi H, Folkers G, editors. **Drug bioavailability estimation of solubility, permeability, absorption, and bioavailability**. 2nd ed. Germany: Wiley-VCH Verlag GmbH & Co.: 2009. p. 135.
- Volak LP, Greenblatt DJ, Moltke LL. *In vitro* approaches to anticipating clinical drug interactions. In: Li AP, editor. **Drug-drug interactions in pharmaceutical development**. New Jersey: Wiley-interscience; 2008. p. 31-74.
- Walle T, Ta N, Kawamori T, Wen X, Tsuji PA, Walle UK. Cancer chemopreventive properties of orally bioavailable flavonoids-methylated versus unmethylated flavones. **Biochem Pharmacol** 2007; 73: 1288-1296.
- Walle K, Walle T. Bioavailability flavonoids: cytochrome P450-mediated metabolism of methoxyflavones. **Drug Metab Dispos** 2007; 35(11): 1985-1989.
- Wang X, Cederbaum AI. Acute ethanol pretreatment increase FAS-mediated liver injury in mice: role of oxidative stress and CYP2E1-dependent and –independent pathways. **Free Rad Biol & Med** 2007; 42: 971-984.
- Watson DG. **Pharmaceutical analysis: A Text book for pharmacy students and pharmaceutical chemists**. China: Elsevier; 2005.
- Wattanapitayakul S, Suwatronnakorn M, Chularojmontri L. *Kaempferia parviflora* ethanolic extract promoted nitric oxide production in human umbilical vein endothelial cells. **J Ethnopharmacology** 2007; 110: 559-562.
- Wattanathorn J, Pangpookiew P, Sripanidkulchai K, Muchimapura S, Sripanidkuchai B. Evaluation of the anxiolytic and antidepressant effects of alcoholic extract of *Kaempferia parviflora* in aged rats. **Am J Agri Bio Sci** 2007; 2(2): 94-98.

- Wattanathorn J, Pangpookiew P, Sripanidkulchai K, Muchimapura S, Sripanidkuchai B. Aprodisiac activity of *Kaempferia parviflora*. **Am J Agri & Biol Sci** 2012; 7(2): 114-120.
- Wen J, Liu B, Yuan E, Ma Y, Zhu Y. Preparation and physicochemical properties of the complex of naringenin with hydroxypropyl- β -cyclodextrin. **Molecules** 2010; 15: 4401-4407.
- Wen X, Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. **Drug Metab Dispo** 2006; 34: 1786-1792.
- Wen X, Walle UK, Walle T. 5,7-dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells. **Carcinogenesis** 2005; 26(4): 803-809.
- Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. **Eur J Pharm Biopharm** 2006; 63: 288-294.
- Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. **Pharm Res** 2004; 21(2): 261-270.
- Yee S. *In vitro* permeability across Caco-2 cells (colonic) can predict *in vivo* (small intestinal) absorption in man-fact or myth. **Pharm Res** 1997; 14(6): 763-766.
- Yenjai C, Prasanphen K, Daodee S, Wongpanich V, Kittakoo P. Bioactive flavonoids from *Kaempferia parviflora*. **Fitoterapia** 2004; 75: 89-92.
- Yenjai C, Sutthanut K, Sripanidkulchai B, Mungkhun N, Wongma C, Mukdasai S, et al. Further studies of bioactive flavonoids from *Kaempferia parviflora*. **KKU Sci J** 2007; 35(1): 37-41.
- Younggil K. **Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists**. New York: Academic publishers; 2002.